Page last updated: 2024-10-24

carteolol and Diabetic Nephropathies

carteolol has been researched along with Diabetic Nephropathies in 1 studies

Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.

Research Excerpts

ExcerptRelevanceReference
"In order to determine the appropriate dosage of carteolol in renal dysfunction, the pharmacokinetics of carteolol has been examined in appropriate patients."1.28Pharmacokinetics of carteolol in patients with impaired renal function. ( Amemiya, M; Asano, Y; Furuya, H; Sakairi, Y; Tabei, K, 1992)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amemiya, M1
Tabei, K1
Furuya, H1
Sakairi, Y1
Asano, Y1

Other Studies

1 other study available for carteolol and Diabetic Nephropathies

ArticleYear
Pharmacokinetics of carteolol in patients with impaired renal function.
    European journal of clinical pharmacology, 1992, Volume: 43, Issue:4

    Topics: Adult; Aged; Carteolol; Chronic Disease; Creatinine; Diabetic Nephropathies; Female; Glomerulonephri

1992